US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Jyong Biotech Ltd.

Volume:- -

Turnover:- -

Market Cap:- -

PE:- -

High:- -

Open:- -

Low:- -

Close:- -

52wk High:- -

52wk Low:- -

Shares:2.67M

Float Shares:- -

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:-5.44%

PB:0.00

PE(LYR):- -

Loading ...

Overview Company News Filings

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

Jyong Biotech Appoints Veteran Capital Markets Executive Wei Zhang as Chief Financial Officer

Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

Jyong Biotech Reports Higher Assets but Deeper Shareholders’ Deficit in June 2025 Unaudited Results

After the recent decline, Jyong Biotech Ltd. (NASDAQ:MENS) CEO Fu-Feng Kuo's holdings have lost 33% of their value

Simply Wall St.

Jyong Biotech Responds to Share Price and Volume Movement

Small U.S. Stocks Close Lower; Jyong Biotech Falls Furthest

Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry

Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs

Jyong Biotech Says Phase 2 Trial of MCS-8 in Prostate Cancer Meets Efficacy Endpoints

MT Newswires Live

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes

Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards

Jyong Biotech Ltd trading resumes

Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/JYB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"JYB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"JYB\",,,,,undefined,":{"symbol":"JYB","market":"US","secType":"STK","nameCN":"Jyong Biotech Ltd.","latestPrice":0,"timestamp":1771621200000,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":0,"shares":2666667,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"02-20 16:00:00 EST","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"listingDate":1744776000000,"exchange":"NASDAQ","adjPreClose":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"JYB\",,,,,undefined,":{"symbol":"JYB","floatShares":0,"roa":"-5.44%","roe":"--","lyrEps":0,"shares":2666667,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"0.00","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/JYB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"JYB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"JYB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"JYB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610800927","title":"Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=2610800927","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610800927?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:30","pubTimestamp":1770903000,"startTime":"0","endTime":"0","summary":"- Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/12/3237195/0/en/Jyong-Biotech-Reports-Transformative-Period-of-Clinical-Validation-and-Commercialization-Attempt-Phase-II-Data-Focuses-on-Dual-Therapeutic-Potential-of-MCS-8-in-Oncology-and-Metabo.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCS","JYB","BK4108","BK4585","BK4588","LABU"],"gpt_icon":0},{"id":"2609142865","title":"Jyong Biotech Appoints Veteran Capital Markets Executive Wei Zhang as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2609142865","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609142865?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:59","pubTimestamp":1770415140,"startTime":"0","endTime":"0","summary":"Jyong Biotech Ltd. ( ($MENS) ) has issued an update. On February 6, 2026, Jyong Biotech Ltd. announced the appointment of Wei (Vivi) Zhang as its n...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/jyong-biotech-appoints-veteran-capital-markets-executive-wei-zhang-as-chief-financial-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/jyong-biotech-appoints-veteran-capital-markets-executive-wei-zhang-as-chief-financial-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JYB","LABU","BK4588","BK4585"],"gpt_icon":0},{"id":"2607450370","title":"Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2607450370","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607450370?lang=en_us&edition=fundamental","pubTime":"2026-01-30 21:30","pubTimestamp":1769779800,"startTime":"0","endTime":"0","summary":"New Taipei City, Taiwan, Jan.  30, 2026  (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to d","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/30/3229525/0/en/Jyong-Biotech-Subsidiary-Announces-Phase-II-Clinical-Data-on-Cholesterol-and-LDH-Indicators-for-MCS-8-PCP-Indicating-Potential-in-Prostate-Cancer-Prevention-and-Metabolic-Value.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCS","JYB","BK4585","BK4588","BK4108","LABU"],"gpt_icon":0},{"id":"2602304586","title":"Jyong Biotech Reports Higher Assets but Deeper Shareholders’ Deficit in June 2025 Unaudited Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2602304586","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602304586?lang=en_us&edition=fundamental","pubTime":"2026-01-10 05:58","pubTimestamp":1767995894,"startTime":"0","endTime":"0","summary":"The latest update is out from Jyong Biotech Ltd. ( ($MENS) ). On January 9, 2026, Jyong Biotech Ltd. furnished unaudited interim condensed consolid...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/jyong-biotech-reports-higher-assets-but-deeper-shareholders-deficit-in-june-2025-unaudited-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/jyong-biotech-reports-higher-assets-but-deeper-shareholders-deficit-in-june-2025-unaudited-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JYB"],"gpt_icon":0},{"id":"2595739955","title":"After the recent decline, Jyong Biotech Ltd. (NASDAQ:MENS) CEO Fu-Feng Kuo's holdings have lost 33% of their value","url":"https://stock-news.laohu8.com/highlight/detail?id=2595739955","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595739955?lang=en_us&edition=fundamental","pubTime":"2025-12-29 18:34","pubTimestamp":1767004440,"startTime":"0","endTime":"0","summary":"Key Insights Insiders appear to have a vested interest in Jyong Biotech's growth, as seen by their sizeable ownership...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mens/jyong-biotech/news/after-the-recent-decline-jyong-biotech-ltd-nasdaqmens-ceo-fu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mens/jyong-biotech/news/after-the-recent-decline-jyong-biotech-ltd-nasdaqmens-ceo-fu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SQQQ","TSYW.SI",".IXIC","QID","QLD","TQQQ","USJW.SI","USAW.SI","JYB","MNQmain","BK4139","NVIW.SI","PSQ","MENS","NQmain"],"gpt_icon":1},{"id":"2592160593","title":"Jyong Biotech Responds to Share Price and Volume Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2592160593","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592160593?lang=en_us&edition=fundamental","pubTime":"2025-12-19 22:00","pubTimestamp":1766152800,"startTime":"0","endTime":"0","summary":"New Taipei City, Taiwan, Dec.  19, 2025  (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”) notes the recent fluctuation in its share price and the increased trad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/19/3208523/0/en/Jyong-Biotech-Responds-to-Share-Price-and-Volume-Movement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JYB"],"gpt_icon":0},{"id":"2592027937","title":"Small U.S. Stocks Close Lower; Jyong Biotech Falls Furthest","url":"https://stock-news.laohu8.com/highlight/detail?id=2592027937","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592027937?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:21","pubTimestamp":1765920060,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies declined Tuesday, as the Russell 2000 Index dropped 0.4%, and the S&P Small Cap 600 Index was down 0.7%.Among companies with a market value of $1 billion to $6.7 billion, Jyong Biotech Ltd. was the biggest laggard during the session, dropping 31%, followed by shares of Frontier Group Holdings Inc., which dropped 11%. Shares of PBF Energy Inc. dropped 11%, Maase Inc. shares plunged 9.0%, and Expro Group Holdings N.V. plunged 8.2%.Tilray Brands Inc. was the best performer, surging 28%, followed by Monte Rosa Therapeutics Inc., which surged 13%. Zenas BioPharma Inc. shares surged 13%, Polibeli Group Ltd. surged 12%, and shares of Sezzle Inc. jumped 10%.Major stock indexes in the U.S. closed mixed Tuesday with the Nasdaq Composite Index increasing 0.2%. Meanwhile, the S&P 500 Index fell 0.2%, and the Dow Jones Industrial Average declined 0.6%.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JYB"],"gpt_icon":0},{"id":"2588822688","title":"Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry","url":"https://stock-news.laohu8.com/highlight/detail?id=2588822688","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588822688?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:30","pubTimestamp":1764855000,"startTime":"0","endTime":"0","summary":"New Taipei City, Taiwan, Dec.  04, 2025  (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/04/3199786/0/en/Jyong-Biotech-Expands-Regional-Partnerships-Signs-MOU-with-a-Vietnam-Pharmaceutical-Distributor-for-MCS-2-Market-Entry.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4108","MCS","JYB"],"gpt_icon":0},{"id":"2585467651","title":"Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2585467651","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585467651?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:30","pubTimestamp":1763991000,"startTime":"0","endTime":"0","summary":"New Taipei City, Taiwan, Nov.  24, 2025  (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/24/3193501/0/en/Jyong-Biotech-Ltd-Signs-Non-Binding-Letter-of-Intent-with-Leading-South-Korean-Pharmaceutical-Company-to-Evaluate-In-Licensing-of-Plant-Derived-MCS-Drugs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4108","JYB","MCS"],"gpt_icon":0},{"id":"2584915852","title":"Jyong Biotech Says Phase 2 Trial of MCS-8 in Prostate Cancer Meets Efficacy Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2584915852","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584915852?lang=en_us&edition=fundamental","pubTime":"2025-11-20 22:46","pubTimestamp":1763649995,"startTime":"0","endTime":"0","summary":"Jyong Biotech  said Thursday that a phase 2 trial of MCS-8 to potentially treat prostate cancer met the efficacy endpoints.The company said the data showed that two years of treatment with MCS-8 led to a 27.3% reduction in prostate cancer incidence and a 17.1% reduction in high-grade prostate cancer, achieving the primary and secondary endpoints respectively.The company also said the investigational drug showed good overall tolerability, providing \"an important foundation\" for potential phase 3 trials.Shares of Jyong were up more than 3% in recent trading Thursday.Price: 30.09, Change: +0.92, Percent Change: +3.14","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4108","MENS","JYB","BK4139","MCS"],"gpt_icon":0},{"id":"2584213248","title":"Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2584213248","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584213248?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:30","pubTimestamp":1763645400,"startTime":"0","endTime":"0","summary":"New Taipei City, Taiwan, Nov.  20, 2025  (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to d","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/20/3191917/0/en/Jyong-Biotech-Announces-Completion-of-Primary-Endpoint-Statistical-Analysis-for-Phase-II-Clinical-Trial-of-MCS-8-With-Positive-Outcomes.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4153","MCS","BK4108","BK4090","JYB","TG"],"gpt_icon":0},{"id":"2571336193","title":"Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2571336193","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571336193?lang=en_us&edition=fundamental","pubTime":"2025-09-29 20:30","pubTimestamp":1759149000,"startTime":"0","endTime":"0","summary":"New Taipei City, Taiwan, Sept.  29, 2025  (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/29/3157728/0/en/Jyong-Biotech-Wins-Innovation-Gold-Award-in-Pharmaceutical-Category-at-2025-Taipei-Biotech-Awards.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BPH","JYB"],"gpt_icon":0},{"id":"2568803299","title":"Jyong Biotech Ltd trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2568803299","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568803299?lang=en_us&edition=fundamental","pubTime":"2025-09-20 04:00","pubTimestamp":1758312015,"startTime":"0","endTime":"0","summary":"16:00 EDT Jyong Biotech (MENS) Ltd trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jyong-biotech-ltd-trading-resumes-thefly-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jyong-biotech-ltd-trading-resumes-thefly-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MENS","BK4139","JYB"],"gpt_icon":0},{"id":"2568477191","title":"Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei","url":"https://stock-news.laohu8.com/highlight/detail?id=2568477191","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568477191?lang=en_us&edition=fundamental","pubTime":"2025-09-18 20:30","pubTimestamp":1758198600,"startTime":"0","endTime":"0","summary":"New Taipei City, Taiwan, Sept.  18, 2025   -- Jyong Biotech Ltd.  , a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs  mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that its chairwoman and chief executive officer, Fu Feng Kuo, has been invited to speak at The 2025 Global Business Forum  on September 19, 2025, at the Taipei International Convention Center. Chairwoman Kuo will join Taiwan biotech industry leaders to discuss the topic, “How can Taiwan align its biotech and medical industries with global trends?”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/18/3152391/0/en/Jyong-Biotech-Chairwoman-and-CEO-Set-to-Attend-as-Speaker-at-2025-Global-Business-Forum-in-Taipei.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JYB","FET","BK4179"],"gpt_icon":0},{"id":"2567020701","title":"Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2567020701","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567020701?lang=en_us&edition=fundamental","pubTime":"2025-09-16 20:18","pubTimestamp":1758025080,"startTime":"0","endTime":"0","summary":"New Taipei City, Taiwan, Sept.  16, 2025  (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to de","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/16/3150776/0/en/Jyong-Biotech-Announces-Completion-of-Patient-Enrollment-of-over-700-subjects-in-Phase-II-Clinical-Trial-of-MCS-8-for-Prostate-Cancer-Prevention.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JYB","MCS","BK4108"],"gpt_icon":0},{"id":"2561347202","title":"Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2561347202","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561347202?lang=en_us&edition=fundamental","pubTime":"2025-08-22 21:00","pubTimestamp":1755867600,"startTime":"0","endTime":"0","summary":"New Taipei City, Taiwan, Aug.  22, 2025  (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to dev","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/22/3137831/0/en/Jyong-Biotech-Ltd-Participated-in-the-22nd-Urological-Association-of-Asia-Congress-to-Display-the-Clinical-Data-for-its-Phase-III-Studies-of-BOTRESO-and-Phase-II-Study-of-MCS-8-PCP.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BPH","MCS","BK4161","III","ITT","LU0053671581.USD","LU0054578231.USD","JYB","BK4108","BK4134"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}